First patient received dose level 2 of RGX-202, a potential one-time AAV Therapeutic for the treatment of Duchenne that includes an optimized transgene for a novel microdystrophin On track for pivotal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results